ATE419267T1 - Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten - Google Patents

Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten

Info

Publication number
ATE419267T1
ATE419267T1 AT04761607T AT04761607T ATE419267T1 AT E419267 T1 ATE419267 T1 AT E419267T1 AT 04761607 T AT04761607 T AT 04761607T AT 04761607 T AT04761607 T AT 04761607T AT E419267 T1 ATE419267 T1 AT E419267T1
Authority
AT
Austria
Prior art keywords
surrogates
peptide binding
containing peptide
macrocycles containing
spacially
Prior art date
Application number
AT04761607T
Other languages
English (en)
Inventor
Pierre Deslongchamps
Yves Dory
Luc Ouellet
Gerald Villeneuve
Mahesh Ramaseshan
Daniel Fortin
Mark Peterson
Hamid Hoveyda
Sylvie Beaubien
Eric Marsault
Original Assignee
Tranzyme Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tranzyme Pharma Inc filed Critical Tranzyme Pharma Inc
Application granted granted Critical
Publication of ATE419267T1 publication Critical patent/ATE419267T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
AT04761607T 2003-07-31 2004-08-02 Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten ATE419267T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49124903P 2003-07-31 2003-07-31
US49125003P 2003-07-31 2003-07-31
US49125303P 2003-07-31 2003-07-31

Publications (1)

Publication Number Publication Date
ATE419267T1 true ATE419267T1 (de) 2009-01-15

Family

ID=34119808

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04761607T ATE419267T1 (de) 2003-07-31 2004-08-02 Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten

Country Status (7)

Country Link
US (2) US7550431B2 (de)
EP (1) EP1648923B1 (de)
JP (1) JP4928263B2 (de)
AT (1) ATE419267T1 (de)
CA (1) CA2533820C (de)
DE (1) DE602004018782D1 (de)
WO (1) WO2005012332A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE42013E1 (en) 2003-06-18 2010-12-28 Tranzyme Pharma Inc. Macrocyclic modulators of the ghrelin receptor
JP4928261B2 (ja) 2003-06-18 2012-05-09 トランザイム・ファーマ・インコーポレイテッド モチリン受容体の大環状拮抗薬
USRE42624E1 (en) 2003-06-18 2011-08-16 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US8921521B2 (en) 2003-06-18 2014-12-30 Ocera Therapeutics, Inc. Macrocyclic modulators of the Ghrelin receptor
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
JP4928262B2 (ja) * 2003-07-31 2012-05-09 トランザイム・ファーマ 薬物発見に有用な空間的に規定された大環状化合物
WO2006046977A1 (en) * 2004-10-26 2006-05-04 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and methods of using the same
JP5122446B2 (ja) * 2005-06-13 2013-01-16 トランザイム・ファーマ，インコーポレイテッド 大環状グレリン受容体アンタゴニストおよびインバースアゴニストならびにその使用方法
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
EP2431380A3 (de) 2006-09-11 2013-07-03 Tranzyme Pharma, Inc. Makrozyklischer Antagonist des Motilinrezeptors zur Behandlung von Magen-Darm-Motilitätsstörungen
BRPI0807046A2 (pt) * 2007-02-09 2015-05-26 Tranzyme Pharma Inc Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
US20080287371A1 (en) * 2007-05-17 2008-11-20 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor for modulation of the migrating motor complex
GB0710863D0 (en) * 2007-06-06 2007-07-18 Glaxo Group Ltd Novel compounds
US8217076B2 (en) * 2008-07-17 2012-07-10 Colorado State University Research Foundation Method for preparing largazole analogs and uses thereof
EP2350031A2 (de) * 2008-08-20 2011-08-03 Ensemble Therapeutics Corporation Makrocyclische verbindungen zur inhibierung des tumornekrosefaktors alpha
EP2401268B1 (de) 2009-02-27 2015-07-29 RaQualia Pharma Inc Oxyindol-derivate mit motilinrezeptor-agonisten-aktivität
AU2010313282A1 (en) 2009-10-30 2012-05-24 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
AU2016230008B2 (en) 2015-03-06 2020-08-27 Colorado State University Research Foundation Synthesis and utility of new capgroup largazole analogs
CA2978698A1 (en) 2015-03-06 2016-09-15 Colorado State University Research Foundation Method for preparing largazole analogs and uses thereof
JP6783311B2 (ja) 2015-09-24 2020-11-11 サイクレニウム ファーマ インコーポレーテッド ヘテロアリール含有大環状化合物のライブラリならびにその製造方法および使用方法
AU2016347456B2 (en) 2015-10-27 2018-12-13 F. Hoffmann-La Roche Ag Peptide macrocycles against acinetobacter baumannii
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
EP3458630A4 (de) * 2016-05-16 2020-01-08 Cyclenium Pharma Inc. Bibliotheken aus verschiedenen makrocyclischen verbindungen und verfahren zur herstellung und verwendung davon
WO2017222935A1 (en) * 2016-06-20 2017-12-28 Kansas State University Research Foundation Small molecule therapeutic inhibitors against picornaviruses, caliciviruses, and coronaviruses
EP3388444A1 (de) 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Antibakterielle peptidmakrozyklen und verwendung davon
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
IL109943A (en) 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
AU4761996A (en) * 1995-01-20 1996-08-07 Molecumetics, Ltd. Conformationally constrained reverse-turn library and methods relating thereto
US6051554A (en) 1995-06-07 2000-04-18 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US5770687A (en) 1995-06-07 1998-06-23 Peptor Limited Comformationally constrained backbone cyclized somatostatin analogs
US5712253A (en) * 1996-06-18 1998-01-27 Abbott Laboratories Macrocyclic 13-membered ring derivatives of erythromycins A and B
US6355613B1 (en) 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
CA2286867A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Combinatorial libraries of peptidomimetic macrocycles and processes therefor
US20020068301A1 (en) 1997-05-28 2002-06-06 Hung-Sen Lai Cyclic peptide libraries and methods of use thereof to identify binding motifs
US6165985A (en) * 1998-02-13 2000-12-26 Solvay Pharmaceuticals Gmbh 11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them
WO2001025251A1 (en) 1999-10-04 2001-04-12 Merck & Co., Inc. Mray gene and enzyme of pseudomonas aeruginosa
CA2284459C (en) * 1999-10-04 2012-12-11 Neokimia Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
WO2002008250A2 (en) * 2000-07-24 2002-01-31 Ardana Bioscience Limited Ghrelin antagonists
EP1312612A4 (de) * 2000-08-24 2004-09-22 Chugai Pharmaceutical Co Ltd Zyklisches peptid-derivat
IL141276A0 (en) 2001-02-05 2002-03-10 Peptor Ltd Backbone cyclized radiolabelled somatostatin analogs
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
JP4928261B2 (ja) * 2003-06-18 2012-05-09 トランザイム・ファーマ・インコーポレイテッド モチリン受容体の大環状拮抗薬
JP4928262B2 (ja) * 2003-07-31 2012-05-09 トランザイム・ファーマ 薬物発見に有用な空間的に規定された大環状化合物
US20090275648A1 (en) * 2005-06-13 2009-11-05 Fraser Graeme L Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same

Also Published As

Publication number Publication date
EP1648923B1 (de) 2008-12-31
US20050119169A1 (en) 2005-06-02
DE602004018782D1 (de) 2009-02-12
US8557765B2 (en) 2013-10-15
WO2005012332A1 (en) 2005-02-10
EP1648923A1 (de) 2006-04-26
US20090312540A1 (en) 2009-12-17
JP2007526895A (ja) 2007-09-20
EP1648923A4 (de) 2006-08-23
CA2533820C (en) 2016-12-13
US7550431B2 (en) 2009-06-23
JP4928263B2 (ja) 2012-05-09
CA2533820A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
ATE419267T1 (de) Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten
CY1111901T1 (el) Χωροταξικα - προσδιορισμενες μακροκυκλικες ενωσεις χρησιμες για την ανακαλυψη φαρμακων
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
SG145725A1 (en) Anti-vegf antibodies
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
WO2005068503A3 (en) M-csf-specific monoclonal antibody and uses thereof
PT1969007E (pt) Composições e métodos para a produção de uma composição
GB2430677A8 (en) Novel antigenbinding polypeptides and their uses
IL171356A (en) Anti-interferon receptor antibody for treatment of inflammatory bowel disease
EP1617802A4 (de) Cngh0010 spezifische polynucleotide, polypeptide, antikörper, zusammensetzungen, verfahren und verwendungen.
MX2007011411A (es) Interaccion rage/diaphanous y composiciones relacionadas y metodos.
EP2083018A3 (de) Zusammensetzungen und Verfahren mit Bezug zu STOP-1
WO2008036337A8 (en) Predicted phosphorylation sites
WO2004037997A3 (en) Fragments and activity of rel protein in m. tuberculosis adn other uses thereof
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
GB0312642D0 (en) Pharmaceutical composition
TW200718711A (en) Polypeptides that bind BR3 and uses thereof
WO2004111180A3 (en) Methods and compositions for selectively enriching microbes
ATE430206T1 (de) Mss4 als antifungisches zielmolekül
WO2006008266A3 (en) Factor xi-binding proteins
DE60319582D1 (de) Cgt1 als antifungales target

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties